Abstract | OBJECTIVE: METHODS: Retrospective analysis of medical charts of 44 women (age 16-38 years) who received CPT for autoimmune diseases. In 33 patients a monthly depot injection of GnRH-a was started before the alkylating agent. The ovarian function [spontaneous menstrual bleeding, hormonal profile, (FSH, LH, E(2), progesterone) pelvic sonography, and conceptions] was evaluated, 1 to 10 years after CPT. RESULTS: In the GnRH-a group, 30 women resumed cyclic ovarian function; 1 (a 37-year-old patient) developed POF (3%), and 2 were lost to follow-up. In the control (no GnRH-a) group, 5 of 11 patients suffered POF (45%). The mean age in the study group was 25.6 ± 5.2 years compared with 29.3 ± 5.8 years in the control group, and the mean cumulative cyclophosphamide dose was 9.9 g compared to 10.9 g, respectively. The difference in the long-term POF remained significant even after adjusting the groups for comparable age and cumulative cyclophosphamide doses. CONCLUSION:
|
Authors | Zeev Blumenfeld, Or Mischari, Naomi Schultz, Nina Boulman, Alexandra Balbir-Gurman |
Journal | Seminars in arthritis and rheumatism
(Semin Arthritis Rheum)
Vol. 41
Issue 3
Pg. 346-52
(Dec 2011)
ISSN: 1532-866X [Electronic] United States |
PMID | 21868068
(Publication Type: Journal Article)
|
Copyright | Copyright © 2011 Elsevier Inc. All rights reserved. |
Chemical References |
- Antirheumatic Agents
- Immunosuppressive Agents
- Gonadotropin-Releasing Hormone
- Cyclophosphamide
|
Topics |
- Adolescent
- Adult
- Antirheumatic Agents
(adverse effects, therapeutic use)
- Autoimmune Diseases
(drug therapy)
- Cyclophosphamide
(adverse effects, therapeutic use)
- Female
- Gonadotropin-Releasing Hormone
(agonists, therapeutic use)
- Humans
- Immunosuppressive Agents
(adverse effects, therapeutic use)
- Lupus Erythematosus, Systemic
(drug therapy)
- Primary Ovarian Insufficiency
(prevention & control)
- Retrospective Studies
|